Mylan acquires rights to two Valeant drugs

Drug maker completes acquisition to treatments for skin conditions

PITTSBURGH — Mylan has completed its acquisition of two skin drugs from Valeant Pharmaceuticals, the generic drug maker said Monday.

Mylan announced that it had acquired the regulatory approval applications for generic clindamycin phosphate and benzoyl peroxide gel, a generic version of Valeant's BenzaClin, and a license to manufacture and market fluorouracil cream in the 5% strength, a version of Valeant's Efudex.

The first drug, which according to IMS Health had sales of about $205 million in 2011, is used to treat acne. The second drug, which had sales of $79 million, is used to treat basal cell carcinomas and actinic or solar keratoses, a skin condition that can be a precursor to skin cancer.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

Login or Register to post a comment.